The widely available steroid dexamethasone may be key in helping to treat Covid-19 patients who require ventilation or oxygen, according to researchers in the United Kingdom. They found that a low-dose regimen of dexamethasone for 10 days reduced the risk of death by a third among hospitalized patients requiring ventilation in the trial.
The findings are preliminary, still being compiled and have not been published in a peer-reviewed journal — but some experts not involved with the study called the results a breakthrough. “This is a major breakthrough: dexamethasone is the first and only drug that has made a significant difference to patient mortality for COVID-19. Potentially preventing 1 death in every 8 ventilated patients would be remarkable,” Nick Cammack, the Covid-19 Therapeutics Accelerator lead at Wellcome Trust in the UK, said in a written statement.
However, hydroxychloroquine and chloroquine, other drugs that have been trialed as treatments for Covid-19 have now had an emergency use authorization revoked by the US Food and Drug Administration. After reviewing the current research available on the drugs, the FDA determined that the drugs do not meet “the statutory criteria” for emergency use authorization as they are unlikely to be effective in treating Covid-19 based on the latest scientific evidence, the agency noted on its website.
Source: CNN Health